Search

Displaying results 5941 - 5950 of 10000 in total
  1. Drug

    Tofisopam

    go.drugbank.com/drugs/DB08811
    Investigational

    The D-enantiomer ([dextofisopam]) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome. … Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe.

  2. Drug

    LErafAON

    go.drugbank.com/drugs/DB04973
    Investigational

    Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.

  3. Drug

    Bumetanide

    go.drugbank.com/drugs/DB00887
    ApprovedInvestigational

    Bumetanide is a sulfamyl diuretic.

  4. Drug

    Oxabolone cipionate

    go.drugbank.com/drugs/DB13185
    Experimental

    It is considered as a performance enhancing drug thus is prohibited from use in sports.

  5. Drug

    Flurbiprofen axetil

    go.drugbank.com/drugs/DB14938
    Investigational

    Flurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients).

  6. Drug

    Pirepemat

    go.drugbank.com/drugs/DB19165
    Investigational

    Pirepemat is under investigation in clinical trial NCT05258071 (A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)).

  7. Drug

    Dihydromyricetin

    go.drugbank.com/drugs/DB15645
    Investigational

    Dihydromyricetin is under investigation in clinical trial NCT03606694 (Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus).

  8. Drug

    Methyl-D9-choline

    go.drugbank.com/drugs/DB12628
    Investigational

    Methyl-D9-choline is under investigation in clinical trial NCT01807910 (ER Stress in NAFLD).

  9. Drug

    Lanopepden

    go.drugbank.com/drugs/DB11912
    Investigational

    Lanopepden has been used in trials studying the treatment of Pneumonia, Infections, Bacterial, Skin Diseases, Infectious, and Skin Infections, Bacterial.

  10. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.